glp 1 drug history The United States GLP-1 Agonists Weight Loss Drugs Market Size & Outlook, 2030 The transformative breakthroughs in GLP-1
Description
Challenges: The prime challenges are high cost, a shortage of competent individuals, and a lack of norms and protocol because of lockdowns and isolation in emerging countries, which are predicted to slow the growth of the GLP-1 agonists market
Secondary market producers, called Compounders, got the go-ahead to start manufacturing and selling GLP-1s in 2022 at a much reduced cost
continues gradually up to 15-18 months
Does Jardiance lower Von Willebrand factor
The drugs may cause a type of eye stroke called nonarteritic anterior ischemic optic neuropathy (NAION)
